Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | NPY1R | P25929 | 3/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.30 |
| ▸ | GALR1 | P47211 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095587 | 0.78 | CHRNA1 (0.34) | CA2CA1 | |
| SCHEMBL1907701 | 0.77 | SMN1; SMN2 (0.36) | — | |
| SCHEMBL13387504 | 0.75 | GPR84 (0.37) | — | |
| SCHEMBL13387526 | 0.75 | MAPT (0.35) | MME | |
| SCHEMBL1907047 | 0.72 | — | — | |
| SCHEMBL1906671 | 0.68 | HDAC3 (0.38) | CA2CA1 | |
| SCHEMBL13553377 | 0.67 | ERAP2 (0.37) | LNPEPERAP2ERAP1 | |
| SCHEMBL16453450 | 0.64 | GLP1R (0.39) | LNPEPERAP2ERAP1 | |
| SCHEMBL3485131 | 0.63 | GLP1R (0.45) | CA2CA1LNPEPERAP2ERAP1 | |
| SCHEMBL3485126 | 0.63 | GLP1R (0.45) | CA2CA1LNPEPERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481494-B2 | Compounds for the treatment of diseases related to protein misfolding | UNIVERSITAT DUISBURG-ESSEN (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | UNIVERSITAT DUISBURG-ESSEN (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2493859-A1 | NEW COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | Universität Duisburg-Essen (DE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011050864-A1 | NEW COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | Universität Duisburg-Essen (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270795-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES RELATED TO PROTEIN MISFOLDING | APP, PRNP, PSEN1 | SSTR3 3071/4885CA2 3346/4885CA12 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.